Evidence map›Paper›PMID 36506611›Full record

ReviewMedicine and pharmacy reports2022

Modern imaging techniques for monitoring patients with multiple myeloma.

Vlad Stefan Pop, Gheorghe Tomoaia, Andrada Parvu

Open access · diamondAbstract readReview
In one paragraph

Review in Medicine and pharmacy reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. The numerous facets of 1q21Oncology letters · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Vlad Stefan PopHematology Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; Hematology Department, "Prof. Dr. Ioan Chiricuta" Oncological Institute, Cluj-Napoca, Romania.
Gheorghe TomoaiaOrthopedics and Traumatology Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Andrada ParvuHematology Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; Hematology Department, "Prof. Dr. Ioan Chiricuta" Oncological Institute, Cluj-Napoca, Romania.
Iuliu Hațieganu University of Medicine and Pharmacy · ROInstitute of Oncology Prof. Dr. Ion Chiricuta · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone disease is a serious problem for many patients, often causing pathological bone fractures. A spinal collapse is a condition that affects the quality of life. It is the most frequent feature of multiple myeloma (MM), used in establishing the diagnosis and the need to start treatment. Because of these complications, imaging plays a vital role in the diagnosis and workup of myeloma patients. For many years, conventional radiography has been considered the gold standard for detecting bone lesions. The main reasons are the wide availability, low cost, the relatively low radiation dose and the ability of this imaging method to cover the entire bone system. Because of its incapacity to evaluate the response to therapy, more sophisticated techniques such as whole-body low-dose computed tomography (WBLDCT), whole-body magnetic resonance imaging, and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (PET/CT) are used. In this review, some of the advantages, indications and applications of the three techniques in managing patients with MM will be discussed. The European Myeloma Network guidelines have recommended WBLDCT as the imaging modality of choice for the initial assessment of MM-related lytic bone lesions. Magnetic resonance imaging is the gold-standard imaging modality for the detection of bone marrow involvement. One of the modern imaging methods and PET/CT can provide valuable prognostic data and is the preferred technique for assessing response to therapy.

Indexed as

18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT)MRImultiple myelomaskeletal surveywhole-body low-dose computed tomography (WBLDCT)

Identifiers

PMID36506611
PMCPMC9694753
OpenAlexW4224291678

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.